TNFSF11 and congenital bilateral aplasia of vas deferens from CFTR mutation: It is known that the recently available biologic drugs neutralizing RANKL and TNF-α, key cytokines in CAVD pathogenesis, are having a great success in the treatment of osteoporosis and arthritis, respectively [135, 136].